So help me decipher...
Overall, including phase 2a and 2b :
15 dogs enrolled.
3 of the 15 were withdrawn as too far gone and MPL didn't help. (Good info to know, treat early.)
1 of the remaining 12 had objective regression.
6 of the remaining 12 has objective stable disease.
12 of 12 completed the 28 day trial. So that leaves me with 5 unaccounted for. All I can assume is because they were not either objective regression or stable, they completed the course of treatment but it had little effect (and therefore may have had the same outcome if untreated).
So is it fair to say 7 out of 15 had a successful outcome with MPL. If so that sounds ok but I am unsure what that is like in comparison to current standards of care. Any vets know?
Also is it an assumption that this has somewhat disproven the biphasic hypothesis? Also good to know.
- Forums
- ASX - By Stock
- NUZ
- Ann: Phase IIb Dog Trial Achieves Interim Clinical Endpoints
Ann: Phase IIb Dog Trial Achieves Interim Clinical Endpoints, page-35
Featured News
Add NUZ (ASX) to my watchlist
(20min delay)
|
|||||
Last
20.0¢ |
Change
0.010(5.26%) |
Mkt cap ! $98.34M |
Open | High | Low | Value | Volume |
20.0¢ | 20.5¢ | 19.5¢ | $86.20K | 429.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 67508 | 19.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.0¢ | 36444 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 67508 | 0.195 |
7 | 258826 | 0.190 |
12 | 723520 | 0.185 |
6 | 377800 | 0.180 |
5 | 151797 | 0.175 |
Price($) | Vol. | No. |
---|---|---|
0.200 | 36444 | 3 |
0.205 | 21529 | 1 |
0.210 | 107676 | 2 |
0.215 | 154400 | 2 |
0.220 | 190000 | 3 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
NUZ (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online